Search Results - "Yardley, D. A."

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER by Yardley, D A, Tripathy, D, Brufsky, A M, Rugo, H S, Kaufman, P A, Mayer, M, Magidson, J, Yoo, B, Quah, C, Ulcickas Yood, M

“…Background: Data characterising long-term survivors (LTS) with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) are…”
Get full text

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics by Lipton, A, Fizazi, K, Stopeck, A.T, Henry, D.H, Smith, M.R, Shore, N, Martin, M, Vadhan-Raj, S, Brown, J.E, Richardson, G.E, Saad, F, Yardley, D.A, Zhou, K, Balakumaran, A, Braun, A

“…Abstract Background Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs)…”
Get full text

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum] by DA, Yardley

“…Yardley DA. Breast Cancer Targets Therapy. 2015:7;293-301.On page 300, Disclosure section, "The author reports no conflicts of interest in the work" has been…”
Get full text

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial by Yardley, D.A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M., Young, R., Bengala, C., Ali, H., Eakel, J., Schneeweiss, A., de la Cruz-Merino, L., Wilks, S., O’Shaughnessy, J., Glück, S., Li, H., Miller, J., Barton, D., Harbeck, N.

“…Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line…”
Get full text

Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial by HAINSWORTH, John D, BURRIS, Howard A, YARDLEY, Denise A, BRADOF, James E, GRIMALDI, Manuel, KALMAN, Leonard A, SULLIVAN, Tim, BAKER, Margaret, ERLAND, Joan B, GRECO, F. Anthony

“…To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer. Forty-one…”
Get full text

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer by Diéras, V., Campone, M., Yardley, D.A., Romieu, G., Valero, V., Isakoff, S.J., Koeppen, H., Wilson, T.R., Xiao, Y., Shames, D.S., Mocci, S., Chen, M., Schmid, P.

“…Increased hepatocyte growth factor/MET signaling is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer (TNBC). We…”
Get full text

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types by Chau, I., Haag, G.M., Rahma, O.E., Macarulla, T.M., McCune, S.L., Yardley, D.A., Solomon, B.J., Johnson, M., Vidal, G.A., Schmid, P., Argiles, G., Dimick, K., Mahrus, S., Abdullah, H., He, X., Sayyed, P., Barak, H., Bleul, C., Cha, E., Drakaki, A.

Get full text

Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck by ROSENTHAL, David I, LEE, Jason H, MILLER, Linda K, FRENKEL, Eugene P, CARBONE, David P, SINARD, Robert, YARDLEY, Denise A, MACHTAY, Mitchell, ROSEN, D. Marc, EGORIR, Merrill J, WEBER, Randal S, WEINSTEIN, Gregory S, CHALIAN, Ara A

“…Paclitaxel is one of the most active agents for squamous cell carcinoma of the head and neck (SCCHN) and an in vitro radiosensitizer. The dose-response…”
Get full text

In pursuit of the prevention of breast cancer by Yardley, D A

Get more information

Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers by Dowell, J E, Sinard, R, Yardley, D A, Aviles, V, Machtay, M, Weber, R S, Weinstein, G S, Chalian, A A, Carbone, D P, Rosenthal, D I

“…The goal of these National Cancer Institute-sponsored phase I trials is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24…”
Get full text

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) by Tolaney, SM, Barry, WT, Dang, CT, Yardley, DA, Moy, B, Marcom, PK, Albain, KS, Rugo, HS, Ellis, M, Shapira, I, Wolff, AC, Carey, LA, Overmoyer, BA, Partridge, AH, Guo, H, Hudis, CA, Krop, IE, Burstein, HJ, Winer, EP

“…Background: Four large randomized phase III trials have reported significant improvements in disease-free (DFS) and overall survival for H administered with…”
Get full text

1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types by Chau, I, Haag, G M, Rahma, O E, Macarulla, T M, McCune, S L, Yardley, D A, Solomon, B J, Johnson, M, Vidal, G A, Schmid, P, Argiles, G, Dimick, K, Mahrus, S, Abdullah, H, He, X, Sayyed, P, Barak, H, Bleul, C, Cha, E, Drakaki, A

Get full text

Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI) by Yardley, D. A., Ismail-Khan, R., Klein, P.

“…Abstract only 268 Background: Hormonal therapy, including AIs, is the mainstay of ER+ breast cancer (BC) treatment; however, both acquired and intrinsic…”
Get full text

METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC) by Schmid, P., Melisko, M., Yardley, D.A., Blackwell, K., Forero, A., Ouellette, G., He, Y., Bagley, R.G., Zhang, J., Vahdat, L.T.

Get full text

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 by Castan, J. Cortes, Verma, S., Hurvitz, S., Krop, I.E., Tripathy, D., Yardley, D.A., Dionne, M., Reynolds, J., Wickham, T., Molnar, I., Miller, K.

Get full text

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) by Cortes Castan, J., Schmid, P., Awada, A., Uppal, H., Tudor, I.C., Blaney, M.E., Steinberg, J.L., Yardley, D.A., Hudis, C., Traina, T.A.

Get full text

Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC) by Hainsworth, J. D., Yardley, D. A., Burris, H. A.

“…Abstract only…”
Get full text

A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer by Traina, T.A., Yardley, D.A., Patel, M.R., Schwartzberg, L.S., Elias, A., Gucalp, A., Blaney, M.E., Gibbons, J., Hudis, C.A., LoRusso, P.

Get full text

Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2 by Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Bousfoul, N., Rugo, H. S., Yardley, D. A.

“…Abstract only…”
Get full text

Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): Subgroup analysis of RIBBON-2 by Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Duenne, A. A., Bousfoul, N., Rugo, H. S., Yardley, D. A.

“…Abstract only 290 Background: In three randomized trials in the first-line metastatic breast cancer (MBC) setting, combining BEV with CT significantly improved…”
Get full text